How advancements in POC testing have impacted health systems
COVID-19 exposed tremendous gaps in health systems and access to testing. Importantly, it also showed the need for rapid and reliable testing in order to safely reopen schools, return to the workplace and reopen the economy.
In this webinar, LumiraDX Chief Innovation Officer Dr. Nigel Lindner, PhD, will review the impact of next-generation point-of-care (POC) testing during the pandemic, and beyond, and explain the science powering this testing technology.
Moving testing from huge, central laboratories to rapid, portable devices has been a pivotal change in medical technology. Previously, testing performance and speed were at odds, but because of recent technological advancements, it’s now possible to deliver both. Next-generation POC testing, different from traditional lateral flow tests, has proven its ability to deliver highly sensitive COVID-19 test results within minutes.
Join this webinar to learn the science behind next-generation POC testing and how providers have integrated this into their patient care during the pandemic.
Speaker
Dr. Nigel Lindner, PhD - Chief Innovation Officer, LumiraDx
Nigel Lindner has a unique combination of scientific, R&D, management and commercial experience, gained across several industries, including both professional and consumer diagnostics, and FMCG businesses. Nigel has a successful track record in delivery of innovative products, having held several senior roles, including CEO of Swiss Precision Diagnostics (SPD), Vice President Global R&D at Alere and senior strategic roles at Unilever R&D.
Message PresenterWho Should Attend?
- Laboratory Director/Manager/Supervisor
- Clinical Laboratory Scientist
- POC Coordinator/Specialist/Manager
- Medical director
- CMO
What You Will Learn
- The impact on health systems by providing lab-quality results at the point of care and how providers have integrated this into their patient care during the pandemic
- The science behind next-generation point of care testing allowing it to uniquely combine sensitivity with speed
- The clinical performance of the LumiraDx SARS-CoV-2 Antigen Test and its correlation with patient infectivity and the SARS-CoV-2 Antibody Test
Xtalks Partner
LumiraDx
LumiraDx develops, manufactures and commercializes an innovative point of care diagnostic Platform, a next generation point of care diagnostic system that combines a small portable Instrument; microfluidic Test Strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform leverages testing methodologies used in lab analyzer systems to deliver lab comparable performance at the point of care in minutes across a broad test menu, in a portable, easy-to-use point of care solution.
LumiraDx recently launched the SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset.
In addition to COVID-19 and other tests already available under CE mark, the Platform integrated several testing technologies and sample types into a single Instrument, allowing continued development across a broad test menu.
Related Webinars
Supporting Antimicrobial Stewardship Using Point of Care CRP Testing
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account